FDA defies advisers; OK's AZ's ovarian cancer drug Lynparza

Even though the FDA's Oncologic Drugs Advisory Committee (ODAC) in June declined to back approval of AstraZeneca's Lynparza (olaparib), an oral inhibitor of polyadenosine 5-diphosphoribose polymerases, in ovarian cancer, the agency defied that advice and granted its blessing anyway on 19 December – although for a slightly different indication.

Even though the FDA's Oncologic Drugs Advisory Committee (ODAC) in June declined to back approval of AstraZeneca's Lynparza (olaparib), an oral inhibitor of polyadenosine 5-diphosphoribose polymerases, in ovarian cancer, the agency defied that advice and granted its blessing anyway on 19 December – although for a slightly different indication.

Shares of AstraZeneca closed at $71.69, down 42 cents.

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category